Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment
For patients with GFR < 60 mL/min, dosage adjustments of crisugabalin should be considered. To maintain comparable plasma drug concentrations in patients with impaired renal function, it is recommended that crisugabalin doses be decreased by approximately 50% for every 50% decline in GFR.
Authors
- Ping Fu (ORCID: https://orcid.org/0000-0002-3061-5925)
- Chao Hu (ORCID: https://orcid.org/0000-0001-5895-6038)
- Shou-Ning Lin
- Ye Wang (ORCID: https://orcid.org/0000-0003-4523-1518)
- Jia Miao (ORCID: https://orcid.org/0000-0002-9810-5243)
- Yanhuan Feng
- Xi Tang (ORCID: https://orcid.org/0009-0007-2066-8218)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Third People's Hospital of Chengdu (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1002/bcp.70310
- Primary Topic
- Infectious Encephalopathies and Encephalitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00